Page 1 Extracted Terms:
- Atrial fibrillation  
- Atrial arrhythmia  
- Heart rhythm  
- Cardiovascular disease  
- Arrhythmia (general)  
- Clinical Practice Guidelines for cardiovascular conditions  
- Diagnosis and management of atrial fibrillation  
- Heart Rhythm Society (related to cardiac rhythm disorders)

Page 2 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation  
- Atrial flutter  
- Atrial arrhythmia (classification, electrical & structural remodeling)  
- Arrhythmia management (catheter ablation, pulmonary vein isolation, surgical ablation)  

- Acute coronary syndrome  
- Coronary artery disease / coronary heart disease  
- Myocardial infarction  
- Percutaneous coronary intervention (PCI)  
- Stents (end‑to‑end, drug‑eluting)  

- Heart failure (HF)  
- Hypertension  
- Diabetes mellitus  
- Obesity / overweight  
- Sleep apnea  
- Alcohol consumption  
- Smoking cessation  
- Caffeine consumption  
- Diet / dietary supplementation  

- Anticoagulation/Antithrombotic therapy  
  - Oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin)  
  - Reversal agents (idarucizumab)  
  - Antiplatelet agents  

- Left atrial appendage (LAA)  
  - LAA occlusion / exclusion / excision (percutaneous and surgical)  

- Thromboembolism / Stroke  
  - Stroke of undetermined cause  
  - Silent/cryptogenic AF  
  - Risk stratification (e.g., CHA₂DS₂‑VASc related concepts)  

- Non‑pharmacologic stroke prevention  
  - Device‑detected atrial high‑rate episodes  

- Risk factor modification / lifestyle changes  
  - Weight loss, physical fitness  

- Clinical evaluation & risk stratification  
  - Rhythm monitoring tools  
  - Basic clinical assessment  

- Management of comorbidities  
  - Blood pressure control, glycemic control, lipid management (implied)  

- Prevention strategies  
  - Primary and secondary prevention of AF and cardiovascular disease  
  - Comprehensive care models  

These terms capture the core cardiovascular concepts, conditions, therapies, and risk‑management strategies referenced throughout the guideline text.

Page 3 Extracted Terms:
- Atrial fibrillation (AF)  
- Acute coronary syndrome (ACS)  
- Percutaneous coronary intervention (PCI)  
- Chronic coronary disease (CCD)  
- Peripheral artery disease (PAD)  
- Chronic kidney disease (CKD)/kidney failure  
- Valvular heart disease (VHD)  
- Atypical arrhythmias  
- Rate control  
- Rhythm control  
- Electrical cardioversion  
- Pharmacologic cardioversion  
- Antiarrhythmic drugs  
- Catheter ablation (AF)  
- Surgical ablation  
- Pacemakers (PM)  
- Implantable cardioverter‑defibrillators (ICDs)  
- Heart failure (HF)  
- Hypertrophic cardiomyopathy (HCM)  
- Adult congenital heart disease (ACHD)  
- Cardiac surgery (post‑operative AF)  
- Critical care (AF in critical illness)  
- Hyperthyroidism (AF trigger)  
- Pulmonary disease (AF precipitant)  
- Pregnancy (AF management)  
- Cardio‑oncology (AF and cancer therapy)  
- Liver disease (anticoagulation considerations)  
- Bleeding risk with anticoagulants  
- Thromboembolism prevention  
- Anticoagulation strategy  
- Periprocedural management  
- Early onset AF (genetic testing)  
- Obesity-related AF  
- WPW syndrome and pre‑excitation  
- Prevention and treatment of post‑operative AF  
- Acute medical illness or surgery (AF context)  

These terms capture the core clinical concepts and patient populations discussed in the guideline excerpt.

Page 4 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left atrial appendage occlusion (LAAO)  
- Catheter ablation of AF  
- Early rhythm control  
- Drug therapy for rhythm control  
- Clinical risk scores (e.g., CHA₂DS₂‑VASc)  
- Stroke and systemic embolism risk  
- Thromboembolic event risk  
- Device‑detected AF  
- Implantable cardiac devices (e.g., pacemakers, defibrillators)  
- Wearable cardiac monitors  
- Obesity, weight loss (as AF risk modifiers)  
- Physical activity (as AF risk modifier)  
- Smoking cessation (as AF risk modifier)  
- Alcohol moderation (as AF risk modifier)  
- Hypertension (as AF risk modifier)  
- Other comorbidities (e.g., diabetes, chronic kidney disease)  
- AF burden (inflammation or arrhythmia load)  
- Sex (non‑modifiable risk factor)  
- Blood pressure control (dynamic risk factor)  
- Ischemic stroke (AF‑related outcome)  
- Clinical practice guidelines (ACC/AHA)  

*(These terms capture the key concepts and therapeutic/factorial elements discussed in the guideline excerpt that are directly related to heart disease and its management.)*

Page 5 Extracted Terms:
- Atrial fibrillation  
- Cardiovascular disease  
- Heart disease  
- Cardiac arrhythmia  
- Guideline‑directed management and therapy (GDMT)  
- Diagnostic testing  
- Pharmacological therapy  
- Procedural treatment  
- Drug treatment regimens  
- Medical devices  
- Randomized controlled trials (RCTs)  
- Systematic reviews  
- Evidence‑based guidelines  
- Shared decision‑making  
- Patient engagement  
- Adherence to recommendations  
- ACC/AHA Joint Committee on Clinical Practice Guidelines  
- Clinical implementation  
- Evidence review committees

Page 6 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Atrial fibrillation  
- Heart defects  
- Congenital heart disease  
- Cardiomyopathy – hypertrophic  
- Heart failure  
- Heart valve diseases  
- Chronic coronary syndromes  
- Left atrial appendage occlusion / exclusion  
- Cardiac surgical procedures  
- Catheter ablation  
- Electrical cardioversion  
- Coronary artery revascularization  
- Stroke prevention (stroke & transient ischemic attack)  
- Management of heart failure  
- Management of arrhythmias in pregnancy  
- Management of adults with congenital heart disease  
- Diagnosis and treatment of hypertrophic cardiomyopathy  
- Management of valvular heart disease  
- Evaluation and diagnosis of chest pain  
- Anticoagulants  
- Rhythm monitoring / rhythm control  
- Rate control  
- Thromboembolism  
- Wolff‑Parkinson‑White syndrome  
- Genetics (cardiovascular genetics)  
- Risk factors: smoking, alcohol, caffeine, sleep, diet, fitness, obesity, diabetes, chronic kidney disease  
- Social determinants of health  

These terms capture the conditions, interventions, management strategies, and risk factors related to heart disease discussed in the guideline.

Page 7 Extracted Terms:
- ACE (angiotensin‑converting enzyme)  
- ACHD (adult congenital heart disease)  
- ACS (acute coronary syndrome)  
- AF (atrial fibrillation)  
- AFL (atrial flutter)  
- AHRE (atrial high‑rate episodes)  
- ARB (angiotensin receptor blocker)  
- AT (atrial tachycardia)  
- AVNA (atrioventricular nodal ablation)  
- BiVP (biventricular pacing)  
- BTK (Bruton’s tyrosine kinase)  
- CABG (coronary artery bypass graft surgery)  
- CAD (coronary artery disease)  
- CCD (chronic coronary disease)  
- BP (blood pressure)  
- BMI (body mass index)  
- bpm (beats per minute)  
- AP (accessory pathway)  
- APT (antiplatelet therapy)  

(Note: the expanded phrases themselves also serve as key heart‑disease terms.)

Page 8 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Congestive heart failure (CHF)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Valvular heart disease (VHD)  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Wolff‑Parkinson‑White (WPW)  
- Peri‑atrial appendage occlusion (LAAO)  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Percutaneous coronary intervention (PCI)  
- Percutaneous left atrial appendage occlusion (pLAAO)  
- Pulmonary venous isolation (PVI)  
- Pulmonary embolism (PE)  
- Pulmonary hypertension (PH)  
- Pulmonary hypertension with pulmonary vascular disease (PHPVD)  
- Coronary heart disease (CHD)  
- Coronary artery procedures / interventions (e.g., coronary artery bypass)  
- Coronary artery disease (CAD) – implicit in CHD  
- Atherosclerosis / plaque (inferred from CVD)  
- Left atrium (LA)  
- Left atrial appendage (LAA)  
- Small left‑ventricular systolic dysfunction (implied by LVEF)  
- Left ventricular ejection fraction (LVEF)  
- Coronary artery disease (CAD) (mentioned in context of PAD)  
- Peripheral artery disease (PAD) – risk factor for CVD  
- Right ventricle / right ventricular pacing (RVP)  
- Renin‑angiotensin‑aldosterone system (RAAS) – modulates heart failure  
- Mineralocorticoid receptor antagonist (MRA) – therapy for HF  
- Direct oral anticoagulant (DOAC) – used in AF management  
- Oral anticoagulant (OAC) therapy  
- Vitamin K antagonist (VKA) – warfarin, etc.  
- Class of Recommendation (COR) – guideline grading of therapies  
- Level of Evidence (LOE) – guideline grading of therapies  
- Guideline‑directed medical therapy (GDMT) – for HF/AF  
- Sleep‑disordered breathing (SDB) – risk factor for AF/CHF  
- Shared decision‑making (SDM) – process in managing heart disease  
- Social determinants of health (SDOH) – influence on cardiovascular risk  
- Quality of life (QOL) – outcome measure in heart disease  
- Hazard ratio (HR) – statistical metric in trials  
- Randomized controlled trial (RCT) – study design in cardiology  

(These terms collectively capture the major clinical, therapeutic, and guideline concepts pertaining to heart disease within the provided text.)

Page 9 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Myocardial infarction (MI)  
- Sudden cardiac death  
- Heart failure (HF)  
- Peripheral artery disease (PAD)

Page 10 Extracted Terms:
- Atrial fibrillation  
- Atrial arrhythmias  
- Atrial tachycardia (AT)  
- AF burden  
- Stroke risk assessment  
- Symptom management (rate‑ and rhythm‑control strategies)  
- Rate control  
- Rhythm control  
- Comorbidities  
- Modifiable risk factors  
- Behavioral change  
- Screening (for all risk factors)  
- Head‑2‑toes (risk‑factor screening tool)  
- SOS (symptom management framework)  
- 4 As (access to all aspects of care)  
- Microreentry circuit  
- Macroreentrant atrial arrhythmia  
- Focal atrial tachycardia  
- Multifocal atrial tachycardia  
- Atrial activation sequence  
- P‑wave morphology  
- Left atrium  
- Right atrium  
- Prevalence of atrial fibrillation  
- Medicare beneficiaries  
- Age group  
- Sex  
- Race

Page 11 Extracted Terms:
- Atrial fibrillation (AF)
- Atrial flutter (AFL)
- Macroreentrant arrhythmia
- Tricuspid annulus
- Cavotricuspid isthmus (CTI)
- Sawtooth flutter waves
- Atrial rhythm
- Sinoatrial node
- Ectopic action potentials
- Pulmonary veins (PVs)
- Interstitial fibrosis
- Reentrant activity
- Atrial tachycardia
- Electrical remodeling
- Calcium handling
- Action potential
- Electrocardiogram (ECG)
- Global Burden of Disease (GBD)
- American Heart Association (AHA)

Page 12 Extracted Terms:
- Atrial fibrillation (AF)  
- Incident AF  
- Risk of AF  
- Life‑style, risk‑factor management (LRFM) program  
- Advancing age  
- Smoking  
- Physical activity / sedentary lifestyle  
- Exercise (including elite/extreme exercise)  
- Alcohol consumption  
- Weight  
- Body‑mass index (BMI)  
- Obesity  
- Weight loss in AF patients  
- Bariatric surgery  
- Height  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Renal denervation  
- Mineral‑corticoid receptor antagonists  
- BP control (post‑ablation)  
- Intensive BP control (SBP <120 mm Hg)  
- Resting heart rate (J‑shaped association)  
- Pulse pressure  
- Cardiac ablation (procedures targeting AF)

Page 13 Extracted Terms:
**Key terms related to heart disease:**

- Atrial fibrillation (AF)  
- Diabetes mellitus  
- Heart failure (HF)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Valvular heart disease (VHD)  
- Cardiac surgery  
- Coronary artery bypass graft (CABG)  
- Post‑operative atrial fibrillation (postop AF)  
- Chronic kidney disease (CKD) (cardiovascular comorbidity)  
- Obstructive sleep apnea (OSA) (cardiovascular risk)  
- Thyroid disease – hyperthyroidism (cardiovascular effect)  
- Sepsis (systemic inflammation impacting heart)  
- Blood glucose / glycemic control  
- Prophylactic amiodarone  
- β‑blockers  
- Posterior left pericardiotomy (surgical technique)

Page 14 Extracted Terms:
- Atrial fibrillation (AF)  
- PR interval  
- PR interval prolongation  
- Polygenic risk score  
- Left ventricular hypertrophy (LVH)  
- BNP (B‑type natriuretic peptide)  
- Natriuretic peptides  
- C‑reactive protein (CRP)  
- Interleukin‑6 (IL‑6)  
- Tumor necrosis factor‑α (TNF‑α)  
- DUSP13  
- FKBP7  
- Spondin‑1  
- IL‑6R  
- TNFS12  
- Lipoprotein(a) (Lp(a))  
- Left atrial (LA) size  
- LA anterior‑posterior dimension  
- LA end‑diastolic volume  
- LA emptying fraction  
- LA ejection fraction  
- Left ventricular posterior wall thickness  
- Genetic susceptibility to AF  
- Education (social determinant)  
- Income (social determinant)  
- BMI (body mass index)  
- Type 2 diabetes  
- Systolic blood pressure (SBP)  
- Smoking  
- Social determinants of health  
- LA reduction surgery  
- Cardiac surgery  
- AF ablation procedures

Page 15 Extracted Terms:
Atrial fibrillation  
Atrial arrhythmia progression  
Atrial conduction velocity  
Atrial conduction block  
Atrial reentry  
L‑type Ca²⁺ current  
IK1 current  
Connexin remodeling  
Gap junctions  
Left atrial (LA)  
Right atrial (RA)  
Heart failure (HF)  
Valve disease (VHD)  
Coronary artery disease (CAD)  
Hypertrophic cardiomyopathy (HCM)  
Neuromuscular disorders  
Thyroid disease  
Atherosclerotic cardiovascular disease (ASCVD)  
Body mass index (BMI)  
Brain natriuretic peptide (BNP)  
Blood pressure (BP) – systolic (SBP) and diastolic (DBP)  
Coronary artery bypass graft surgery (CABG)  
Chronic kidney disease (CKD)  
Electrocardiogram (ECG)  
Hazard ratio (HR)  
Left ventricular (LV)  
Left ventricular hypertrophy (LVH)  
Obstructive sleep apnea (OSA)  
Valvular heart disease (VHD)

Page 16 Extracted Terms:
**Key Terms Related to Heart Disease Extracted from the Text**

1. Atrial fibrillation (AF)  
2. Atrial cardiomyopathy  
3. Atrial structural remodeling  
4. Atrial electrical remodeling  
5. Sarcoplasmic reticulum calcium‑ATPase (SERCA)  
6. Phospholamban  
7. Sarcolipin  
8. Late sodium current (I<sub>Na,late</sub>)  
9. Cardiac glycosides  
10. Sodium‑calcium exchanger (NCX)  
11. Calcium‑calmodulin‑dependent protein kinase II (CaMKII)  
12. Ryanodine receptor 2 (RyR2)  
13. Delayed afterdepolarizations (DADs)  
14. Premature atrial contractions (PACs)  
15. Left atrial (LA) volume  
16. N‑terminal pro‑brain natriuretic peptide (NT‑proBNP)  
17. Myofibroblast activation  
18. Collagen deposition (fibrosis)  
19. Fibrofatty deposits  
20. Altered ion‑channel expression  
21. Calcium signaling dysregulation  
22. Inflammatory infiltrates  
23. Myeloperoxidase (MPO) activity  
24. Von Willebrand factor (vWF)  
25. Vascular cell adhesion molecule‑1 (VCAM‑1)  
26. Monocyte chemoattractant protein‑1 (MCP‑1)  
27. Thrombus formation  
28. Cerebral stroke (as a thrombotic complication)  
29. Atrial dilation  
30. Atrial myocyte hypertrophy  
31. Extracellular matrix remodeling  
32. Vascular dysfunction  
33. Atrial ectopy  
34. Effective refractory period (ERP)  
35. Conduction velocity / dispersion of repolarization  
36. Reentry circuits  
37. Pulmonary veins (PV)  
38. Pulmonary vein isolation (PVI)  
39. Action potential alternans  
40. Oxidative stress  
41. Inflammatory signaling pathways  

These terms encapsulate the major pathophysiologic entities, biomarkers, cellular mechanisms, and clinical manifestations discussed in the provided guideline excerpt.

Page 17 Extracted Terms:
- Atrial fibrillation (AF)  
- Clinical atrial fibrillation  
- Subclinical atrial fibrillation  
- Atrial high‑rate episode  
- AF burden  
- First documented AF  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Long‑standing persistent atrial fibrillation  
- Permanent atrial fibrillation  
- Valvular atrial fibrillation  
- Non‑valvular atrial fibrillation  
- Lone atrial fibrillation  
- Supraventricular tachyarrhythmia  
- Irregular R‑R intervals  
- P waves  
- Fibrillatory waves  
- 12‑lead electrocardiogram (ECG)  
- Rhythm strip  
- Wearable cardiac monitor  
- Intracardiac electrogram  
- Implanted cardioverter‑defibrillator (ICD)  
- Pacemaker  
- Implantable loop recorder  
- Upstream pathways  
- Inflammation  
- Oxidative stress  
- Fibrosis  
- Calcium handling  
- Genetic factors  
- Metabolic factors  
- Obesity  
- Renin‑angiotensin‑aldosterone system (RAAS)  
- Angiotensin‑converting enzyme (ACE) inhibitor  
- Angiotensin‑II receptor blocker (ARB)  
- Blood pressure  
- Vascular smooth‑muscle constriction  
- Atrial interstitial collagen  
- Reactive oxygen species  
- Sympathetic nervous system  
- Calcium‑dependent calmodulin kinase II  
- Ryanodine receptor phosphorylation  
- Late sodium current (INa,L)  
- Calcium current amplitude  
- Reactive lipid products (isolevuglandins)  
- Nuclear factor‑κB (NF‑κB)  
- NLRP3 inflammasome  
- Mitochondrial stress  
- Myofilament protein degradation  
- Atrial contractility  
- Thromboembolism risk  
- Stroke risk reduction  
- Vitamin K antagonists  
- Non‑Vitamin K antagonist oral anticoagulants (NOACs)  
- Native valvular heart disease  
- Mitral stenosis  
- Prosthetic heart valves  
- Moderate to severe valvular disease

Page 18 Extracted Terms:
- Atrial fibrillation (AF)  
- Systemic inflammatory activation  
- Non‑surgical atrial fibrillation  
- NLRP3 inflammasome  
- NLRP3 knockdown  
- AF inducibility  
- AF pathophysiology  
- Persistence of atrial fibrillation  
- Substrate for AF  
- Refractory period  
- Conduction velocity  
- Heterogeneous conduction velocity  
- Repolarization duration  
- Fibrotic atria  
- Fatty atria  
- Interstitial fibrosis  
- Adipose infiltration  
- Electrophysiologic remodeling  
- Autonomic Nervous System (ANS)  
- Sympathetic efferent stimulation  
- Noradrenaline  
- β‑adrenergic receptors  
- L‑type calcium channels  
- Delayed afterdepolarization  
- Calcium overload  
- Ryanodine receptor dysfunction  
- Parasympathetic stimulation  
- Atrial effective refractory period  
- IKACh  
- Acetylcholine‑receptor‑mediated inward rectifying potassium channel  
- Sympathetic activity  
- Parasympathetic activity  
- Atrial flutter  
- Macroreentrant atrial tachycardia  
- Reverse typical flutter  
- Lower‑loop flutter  
- Low right atrial isthmus  
- Left mitral isthmus flutter  
- Scar‑mediated reentrant tachycardia  
- Cardiac surgery  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation

Page 19 Extracted Terms:
- Atrial fibrillation (AF)  
- Autonomic nervous system (ANS) dysfunction  
- Autonomic afferent reflex deficiencies  
- Cardiac volume changes  
- Sympathetic activity  
- Atrial sympathetic hyperinnervation  
- Atrial parasympathetic hyperinnervation  
- Spatial heterogeneity of atrial tissue  
- Electrical fractionation in the atria  
- Altered atrial electrophysiology  
- AF substrate (reentry substrate)  
- Modifiable AF risk factors  
- Blood volume and pressure homeostasis disturbances  
- Heart failure (HF)  
- Atrial dilatation (atrial remodeling)  
- Genetic predisposition to AF  
- TTN loss‑of‑function variants  
- MYH7 and MYH6 variants  
- LMNA variants  
- KCNQ1 variants  
- Inherited cardiomyopathy genes  
- Arrhythmia‑syndrome genes  
- Myocardial structural proteins  
- Ion channel genes  
- Premature atrial contraction (PAC)  
- NLRP3 (NOD‑, LRR‑, and pyrin domain‑containing protein 3)  
- Renin‑angiotensin‑aldosterone system (RAAS)  
- Reentrant arrhythmic activity (arrhythmic triggers)

Page 20 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Anticoagulation therapy  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Left atrium (LA)  
- Heart rate variability (HRV)  
- Autonomic nervous system (ANS)  
- Heart failure (HF)  
- Guideline‑directed medical therapy (GDMT)  
- Stroke‑risk reduction therapies  
- Quality of life (QOL)  
- Adverse cardiovascular outcomes  

Page 21 Extracted Terms:
**Key Heart‑Disease Terms**

1. Atrial Fibrillation (AF)  
2. Catheter Ablation  
3. Rhythm Control Therapy  
4. Rate Control Therapy  
5. Catheter Ablation vs Antiarrhythmic Drugs  
6. Direct Oral Anticoagulants (DOAC)  
7. Oral Anticoagulation (OAC)  
8. Stroke (ischemic stroke, thromboembolic events)  
9. Heart Failure (HF) – including systolic HF  
10. Coronary Artery Disease (CAD)  
11. Chronic Obstructive Pulmonary Disease (COPD)  
12. Hypertension  
13. Elderly (age ≥ 75 years)  
14. Percutaneous Left Atrial Appendage Occlusion (LAAO)  
15. CHARGE‑AF Risk Prediction Model  
16. C2HEST Score (coronary artery disease, COPD, hypertension, elderly, systolic HF, thoracic aortic enlargement)  
17. Cardiac Risk Stratification  
18. Population Screening for AF  
19. Cardioversion  
20. Anticoagulation Decision Aid (clinical tool)  

These terms capture the primary cardiovascular conditions, procedures, therapies, risk models, and decision‑support tools discussed in the guidelines.

Page 22 Extracted Terms:
- Atrial fibrillation (AF)  
- Arrhythmias  
- Wolff‑Parkinson‑White (WPW) syndrome  
- Bradycardia  
- QT interval prolongation  
- Cardiac structure  
- Transthoracic echocardiography  
- Echocardiography (echo)  
- Chamber size  
- Cardiac function (systolic, diastolic)  
- Valve function  
- Valvular pathology  
- Coronary artery disease (CAD)  
- Chronic obstructive pulmonary disease (COPD)  
- Hypertension  
- Elderly (age ≥ 75 y)  
- Systolic heart failure (HF)  
- Thyroid disease (hyperthyroidism)  
- Myocardial infarction (MI)  
- Myocardial ischemia  
- Acute coronary syndrome (ACS)  
- Pulmonary embolism (PE)  
- Stroke (ischemic and hemorrhagic)  
- Systemic embolism  
- Thromboembolism risk  
- Bleeding risk  
- Hemorrhage risk  
- Hazard ratio (HR)  
- Risk stratification  
- CHARGE‑AF risk score  
- C2HEST risk score  
- Artificial‑intelligence (AI) algorithm for AF detection  
- Smartwatch‑based AF screening app  
- Electrocardiographic monitoring (intermittent, continuous)  
- Consumer‑based ECG devices  
- Short‑term cardiac monitoring  
- Cost‑effective screening  

These terms capture the major heart‑disease concepts and tools discussed in the guideline excerpt.

Page 23 Extracted Terms:
- Atrial fibrillation (AF)  
- Left ventricular ejection fraction (LVEF)  
- Right ventricular (RV) pressure  
- Anti‑arrhythmic drug therapy  
- Catheter ablation  
- Strain imaging  
- Infiltrative cardiomyopathy  
- Amyloidosis  
- Echocardiography  
- Left atrial (LA) size  
- Left atrial function  
- Left atrial compliance  
- AF recurrence  
- Left atrial strain (LA strain)  
- Left atrial volume (LA volume)  
- Chronic kidney disease (CKD)  
- Liver dysfunction  
- Hyperthyroidism  
- Electrolyte abnormalities  
- Myocardial ischemia  
- Acute coronary syndrome (ACS)  
- Pulmonary embolism (PE)  
- Myocardial stress imaging  
- Ischemic myocardium  
- Revascularization  
- Rhythm monitoring  
- Intracardiac rhythm device  
- Atrial pacemaker lead  
- Implantable cardiac monitor (ICM) / implantable loop recorder  
- Cardiac rhythm management device (CRMD) with atrial lead (e.g., pacemaker, defibrillator)  
- Handheld electrocardiogram (ECG)  
- Smartwatch ECG  
- Photoplethysmography (PPG)  
- Automated algorithms for AF detection  
- AF frequency, duration, and burden  
- Stroke risk assessment  
- Bleeding risk assessment  
- Valvular disease (significant valvular disease)

Page 24 Extracted Terms:
- Atrial fibrillation (AF)  
- Electrocardiographic tracings  
- Photoplethysmography  
- Smartphones  
- Smartwatches  
- Cardiac rhythm devices with atrial lead  
- Stroke  
- Anticoagulation  
- Oral anticoagulation  
- Implantable cardiac monitors  
- External cardiac monitors  
- Cardioversion  
- AF ablation  
- Quality of life (QOL)  
- Lifestyle and risk factor modification (LRFM)  
- Obesity  
- Physical inactivity  
- Unhealthy alcohol consumption  
- Binge drinking  
- Smoking  
- Diabetes mellitus  
- Hypertension (high blood pressure)  
- Cannabis use  
- Cocaine use  
- Methamphetamine use  
- Opiate use  
- High‑intensity endurance training  
- High‑volume exercise (≥3 h/day)  
- High‑intensity vigorous activity  
- High‑rate episodes detected by devices  
- Device‑detected atrial high‑rate episodes  
- Monitoring period  
- Sensitivity of AF detection  
- Accuracy of automated algorithms  
- Intracardiac tracings  
- Frequency of AF  
- Duration of AF  
- Burden of AF  
- Risk prediction models for AF  
- Genetic risk factors for AF  
- Family history of AF  
- Cardiovascular health  
- Ideal weight / weight loss strategy  
- Smoking cessation counseling  
- Alcohol moderation (≤1 standard drink/day)  
- Glucose control (diabetes management)  
- Blood pressure control (GDMT)  
- Cardiovascular risk factors  
- Observational study evidence on AF risk  
- J‑curve risk of vigorous activity  
- Linear relationship between alcohol consumption and AF risk.

Page 25 Extracted Terms:
Atrial fibrillation (AF)  
Atrial myocardium  
Obesity  
Body mass index (BMI)  
Weight loss  
Type 1 diabetes  
Type 2 diabetes  
Hypertension  
Blood‑pressure control  
Cardiovascular disease (CVD)  
Sinus rhythm  
Postoperative atrial fibrillation (post‑operative AF)  
Post‑ablation atrial fibrillation (post‑ablation AF)  
Arrhythmia burden  
Functional capacity  
Quality of life (QoL)  
Health‑related QoL  
Aerobic exercise  
Physical fitness  
Cardiopulmonary fitness  
Exercise prescription  
Bariatric surgery  
Secondary prevention  
Risk factors  
Smoking cessation  
Incidence of AF  
AF symptoms  
AF recurrence  
AF progression to persistent AF  
Reversal of AF type  
Attributable risk for AF  
Intensive BP control  
Lifestyle‑risk‑factor‑management (LRFM)  
Structured weight‑loss program  
Moderate‑to‑vigorous intensity exercise  
210‑minute‑per‑week target  
Ventricular‑rate control during exercise


Page 26 Extracted Terms:
- Atrial fibrillation (AF)  
- AF recurrence  
- AF burden  
- AF symptoms  
- Paroxysmal AF  
- Persistent AF  
- Arrhythmia recurrence  
- Cardiac rehabilitation  
- Exercise training  
- High‑intensity aerobic exercise  
- Moderate‑intensity activity  
- Ablation (AF ablation)  
- Catheter ablation  
- Warfarin  
- Therapeutic range  
- Cardiovascular risk factors  
- Smoking cessation  
- Tobacco cessation  
- Smoking  
- Alcohol consumption  
- Alcohol abstinence / reduction  
- Caffeine consumption  
- Caffeine abstention  
- Stroke  
- Heart failure (HF)  
- Hospitalization  
- All‑cause mortality  
- Cardiovascular complications  
- Behavioral interventions  
- Pharmacotherapy  
- Guideline‑directed medical therapy (GDMT)

Page 27 Extracted Terms:
- Atrial fibrillation (AF)  
- Cardiovascular disease  
- Hypertension (high blood pressure)  
- Cardiovascular mortality  
- Sudden cardiac death  
- Blood pressure (BP) control  
- Stroke (cerebro‑vascular event)  
- Bleeding (anticoagulation‑related)  
- Arterial disease (atherosclerosis)  
- Diabetes mellitus (type 2)  
- Glycemic control  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Catheter ablation for AF  
- Pulmonary vein isolation (PVI)  
- Renal denervation  
- Mineralocorticoid receptor antagonists (MRAs)  
- ACE inhibitors (angiotensin‑converting enzyme inhibitors)  
- Angiotensin II receptor blockers (ARBs)  
- Integrated lifestyle‑risk‑factor‑modification programs (LRFM)  
- Arrhythmia‑free survival  
- AF burden  
- AF recurrence  
- Caffeine consumption (effects on AF)  
- Omega‑3 fatty acids  
- Vitamin D supplementation (peri‑operative)  
- Ascorbic acid (vitamin C)  
- Weight management  
- Low‑carbohydrate diet (risk of AF)  
- Dietary supplements (omega‑3, vitamin D, vitamin C)

Page 28 Extracted Terms:
- Atrial fibrillation (AF)  
- Obstructive sleep apnea (OSA)  
- Sleep‑disordered breathing (SDB)  
- Incident atrial fibrillation  
- AF recurrence  
- AF burden  
- Cardioversion  
- Catheter ablation  
- Pulmonary vein isolation (PVI)  
- Thromboembolism  
- Stroke  
- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- Epworth Sleepiness Scale  
- Obesity  
- Alcohol use  
- Low‑risk factor management (LRFM)  
- Anticoagulation therapy  
- Mineralocorticoid receptor antagonists  
- Statins  
- Angiotensin‑converting enzyme inhibitors (ACE‑inhibitors)  
- Angiotensin receptor blockers (ARBs)  
- Cardiac rehabilitation  
- Comprehensive heart‑disease care  
- Integrated multidisciplinary care  
- Nurse‑led AF clinics  
- Clinical care pathways  
- Clinical decision support systems  
- Cardiovascular outcomes  
- All‑cause mortality  
- Cardiovascular risk factors  
- Sleep‑disordered breathing screening  
- Rhythm‑control strategies  
- Rate‑control strategies.

Page 29 Extracted Terms:
- Atrial fibrillation (AF)  
- Thromboembolism  
- Stroke (including transient ischemic attack)  
- Anticoagulation therapy  
- Bleeding risk  
- CHA2DS2‑VASc score  
- HAS‑BLED score  
- CHADS2 score  
- ATRIA risk score  
- GARFIELD‑AF risk score  
- Congestive heart failure  
- Hypertension  
- Advanced age (≥65 years, ≥75 years)  
- Diabetes mellitus  
- Renal disease  
- Hepatic / liver disease  
- Anemia  
- Malignancy  
- Alcohol / ethanol abuse  
- Platelet count or function abnormalities  
- Genetic factors influencing bleeding  
- Re‑bleeding risk  
- INR instability (labile INR)  
- Risk stratification  
- Clinical decision support (CDS)  
- Mobile health technology (mHealth)  
- Stroke prevention strategies  
- Thromboembolic events  
- Stroke/TIA
- Cerebrovascular disease  
- Cardiovascular disease  
- Heart disease  
- Clinical risk scoring  
- Risk discrimination (c‑index)  
- Bleeding risk scoring  
- Clinical outcomes in AF management

Page 30 Extracted Terms:
- Atrial fibrillation (AF)  
- Congestive heart failure  
- Left atrial appendage (LAA)  
- Left atrium (LA)  
- Ischemic stroke (cerebrovascular accident)  
- Hemorrhagic stroke/bleeding  
- Anticoagulant therapy  
- Direct oral anticoagulants (DOACs)  
- Vitamin K antagonists (VKAs)  
- CHA2DS2‑VASc risk score  
- ATRIA risk score  
- GARFIELD‑AF risk score  
- HAS‑BLED bleeding risk score  
- HEMORR2HAGES bleeding risk score  
- Anti‑platelet medications  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Left atrial thrombus  
- Atrial thromboembolism  
- Antithrombotic treatment  
- Atrial fibrillation burden  
- Electrocardiographic features (e.g., atrial ectopy)  
- Biologic markers for cardiac risk (e.g., proBNP)  
- Blood pressure control (hypertension)  
- Cardiovascular risk factors (diabetes mellitus, vascular disease)

Page 31 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Thromboembolic events  
- Oral anticoagulation  
- HAS‑BLED score  
- HEMORR2HAGES score  
- ATRIA score  
- Risk score  
- Bleeding risk  
- Stroke risk  
- Net clinical benefit  
- Risk‑based selection  
- Paroxysmal AF  
- Persistent AF  
- Long‑standing persistent AF  
- Permanent AF  
- Reassessment interval  
- Thromboembolism  
- Stroke prevention  
- Anticoagulation therapy

Page 32 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Systemic embolism  
- Congestive heart failure (CHF)  
- Heart failure  
- Oral anticoagulation  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Anticoagulation therapy  
- CHADS2 score  
- CHA₂DS₂‑VASc score  
- ATRIA score  
- GARFIELD‑AF score  
- MCHA₂DS₂‑VASc score  
- International normalized ratio (INR)  
- Bleeding risk  
- Renal function  
- Glomerular filtration rate (GFR)  
- Proteinuria  
- Hypertension  
- Diabetes mellitus  
- Vascular disease  
- Age (risk factor)  
- Sex (female)  
- Transient ischemic attack (TIA)  
- Mortality  
- Quality of life (QOL)  
- Cardiac arrhythmia  
- Cardiovascular disease  
- Clinical safety

Page 33 Extracted Terms:
- Atrial fibrillation (AF)  
- Mitral stenosis  
- Mechanical heart valve  
- Oral anticoagulants (OAC)  
- Direct oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban  
- Warfarin  
- International Normalized Ratio (INR)  
- Thromboembolism  
- Stroke (ischemic)  
- Systemic embolism  
- Intracranial hemorrhage (ICH)  
- Gastrointestinal bleeding  
- Antithrombotic therapy  
- Aspirin  
- Clopidogrel  
- CHA2DS2‑VASc score  
- Heart failure (HF)  
- Right‑sided heart failure signs – elevated central venous pressure, hepatomegaly, dependent edema  
- Left‑sided heart failure signs – exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion  
- Hypertension  
- Diabetes mellitus  
- Age ≥65 years  
- Age ≥75 years  
- Obesity (BMI ≥ 30 kg/m²)  
- Hypertrophic cardiomyopathy (HCM)  
- Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²  
- Proteinuria > 150 mg/24 h  
- Enlarged left atrial (LA) volume ≥ 73 mL  
- LA diameter ≥ 4.7 cm  
- Ischemic stroke  
- Transient ischemic attack (TIA)  
- Peripheral embolism  
- Pulmonary embolism (PE)  
- Coronary artery disease (CAD) – prior myocardial infarction, angina pectoris, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)  
- Peripheral vascular disease – intermittent claudication, vascular surgery or intervention (abdominal aorta, lower extremity vessels)  
- Arterial and venous thrombosis.

Page 34 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Valvular heart disease  
- Left ventricular dysfunction  
- Congestive heart failure  
- Hypertension  
- Diabetes mellitus  
- Stroke  
- Transient ischemic attack (TIA)  
- Thromboembolism  
- Systemic embolism  
- Intracranial hemorrhage (ICH)  
- Factor Xa inhibitors  
- Vitamin K antagonists (e.g., warfarin)  
- Direct oral anticoagulants (DOACs)  
- Anticoagulation therapy  
- Antiplatelet therapy  
- CHA₂DS₂‑VASc risk score  
- CHADS₂ risk score  
- ATRIA risk score  
- GARFIELD‑AF (risk score)  
- Risk stratification  
- Female sex (as risk modifier)  
- Age ≥ 75 years  
- Age 65–74 years  
- Anemia (as risk factor)  
- Renal disease (as risk factor)  
- Prior bleeding (as risk factor)  
- Vascular disease  
- Stroke prevention  
- Thromboembolic event rates  
- Anticoagulant‑vs‑antiplatelet comparison  
- Stroke‑risk scores  
- Anticoagulant‑selection guidelines for valvular heart disease  
- Atrial fibrillation‑valvular heart disease management  
- Atrial fibrillation‑atrial flutter co‑management  
- Stroke‑risk assessment  
- Antithrombotic selection in valvular heart disease.

Page 35 Extracted Terms:
- Atrial fibrillation  
- Stroke  
- Systemic embolism  
- Anticoagulation  
- Warfarin (vitamin K antagonist)  
- Direct oral anticoagulants (DOACs)  
- Dabigatran  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- CHADS₂ score  
- Intracranial hemorrhage (ICH)  
- Major bleeding  
- Hypertrophic cardiomyopathy  
- Mitral stenosis  
- Mechanical heart valve  
- Valvular heart disease (VHD)  
- Aortic stenosis  
- Aortic regurgitation  
- Mitral regurgitation  
- Bioprosthetic valve  
- Valve repair  
- Antiplatelet therapy (APT)  
- Aspirin  
- Clopidogrel  
- Coronary artery disease (CAD)  
- Vascular disease  
- Myocardial infarction (MI)  
- Stroke risk threshold  
- Time in therapeutic range (TTR)  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- Clinical guideline  
- Stroke prevention in atrial fibrillation  
- VKA (vitamin K antagonist)  
- DOAC‑warfarin comparison  
- Therapeutic INR  
- Stroke risk stratification  
- Embolic stroke prevention  
- Antithrombotic strategy  
- Stroke and systemic embolism risk  
- Stroke rate in AF trials  
- Antiplatelet vs anticoagulant efficacy  
- Stroke prevention guidelines in AF  

(These terms capture the key heart‑disease concepts, conditions, risk assessments, treatments, and guideline references presented in the text.)

Page 36 Extracted Terms:
- Atrial Fibrillation (AF)  
- Stroke (cardioembolic, non‑cardioembolic)  
- Anticoagulants  
- Direct Oral Anticoagulants (DOACs)  
- Warfarin  
- International Normalized Ratio (INR)  
- Time in Therapeutic Range (TTR)  
- Thromboembolism  
- Major bleeding  
- Intracerebral Hemorrhage (ICH)  
- Peripheral embolization  
- Cardioembolic stroke  
- Stroke prevention  
- Antithrombotic therapy  
- Drug interactions (CYP3A4, P‑glycoprotein)  
- Renal function (creatinine clearance)  
- Hepatic function  
- Mechanical heart valves  
- Anticoagulant dosing  
- Aspirin therapy for AF  
- Drug‑driven bleeding risk  
- Bleeding risk assessment  
- Medication adherence  
- Adverse effects of anticoagulation  

Page 37 Extracted Terms:
Atrial Fibrillation  
OAC (Oral Anticoagulant)  
Anticoagulant Therapy  
Warfarin  
Vitamin K Antagonist  
Direct Thrombin Inhibitor  
Factor Xa Inhibitor  
Dabigatran  
Rivaroxaban  
Apixaban  
Edoxaban  
CYP2C9  
CYP1A2  
CYP3A4  
CYP3A5  
p‑Glycoprotein  
CrCl (Creatinine Clearance)  
Renal Dosing Adjustment  
INR (International Normalized Ratio)  
Drug Interaction Management (CYP3A4 / p‑Glycoprotein)

Page 38 Extracted Terms:
- Atrial fibrillation (AF), non‑valvular AF  
- Silent atrial fibrillation  
- Stroke, ischemic stroke  
- Transient ischemic attack (TIA)  
- Systemic embolism  
- Thromboembolism, thromboembolic events  
- Direct oral anticoagulants (DOACs)  
- Warfarin (vitamin K antagonist, VKA)  
- International Normalised Ratio (INR)  
- INR monitoring, INR control, therapeutic INR goal  
- CYP3A4 / P‑glycoprotein–inducing agents  
- Mechanical heart valve  
- Moderate‑severe mitral stenosis  
- Anticoagulant drug‑drug interactions  
- Antiepileptic drugs (CYP‑inducing)  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Selective serotonin reuptake inhibitors (SSRIs)  
- Antimicrobial agents  
- Antiplatelet therapy (APT)  
- Implantable loop recorder  
- Cardiac monitoring for AF detection  
- Off‑label DOAC dosing (underdosing, overdosing)  
- Bleeding risk (clinically relevant bleeding, major bleeding)  
- Net clinical outcome, all‑cause mortality related to anticoagulation  
- Oral anticoagulant (OAC)  
- Child‑Pugh scoring (liver function impact on anticoagulant dosing)

Page 39 Extracted Terms:
- Atrial Fibrillation  
- Direct Oral Anticoagulant (DOAC)  
- HAS-BLED score  
- Uncontrolled hypertension  
- Renal function (serum creatinine, dialysis, kidney transplant)  
- Hepatic function (bilirubin, ALT/AST/AP, cirrhosis)  
- Stroke (hemorrhagic or ischemic)  
- Bleeding history or predisposition  
- Labile INR (time in therapeutic range)  
- Elderly age (≥65 years)  
- Antiplatelet agents  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Excessive alcohol intake (≥8 units/week)  
- Child‑Pugh score (liver disease severity)  
- Encephalopathy  
- Ascites  
- Total bilirubin  
- Albumin  
- INR (international normalized ratio)  
- Creatinine clearance (CrCL) based on actual body weight  
- International Normalized Ratio (INR)  
- Cirrhosis  
- Liver disease severity (Child‑Pugh A, B, C)

Page 40 Extracted Terms:
- Atrial fibrillation (AF)  
- Occult atrial fibrillation  
- Cryptogenic stroke  
- Transient ischemic attack (TIA)  
- Antiplatelet therapy (APT)  
- Anticoagulation (oral anticoagulants)  
- CHA₂DS₂‑VASc score  
- Systemic embolism  
- Device‑detected atrial high‑rate episode (AHRE)  
- Implantable loop recorder  
- External loop recorder  
- Holter monitoring  
- Cardiac monitoring  
- Extended cardiac monitoring  
- Implantable electronic device  
- Stroke risk reduction  
- Embolic stroke  
- Stroke risk factors  
- Cardiovascular implantable electronic device (CIED)  
- Risk‑based decision framework (shared decision making, SDM)  
- Clinical guidelines  
- Randomized controlled trials (RCTs)  
- EMRACTICE, CRYSTAL‑AF, FIND‑AF, PER DIEM, ASSERT (trial names)

Page 41 Extracted Terms:
- Atrial fibrillation (AF)  
- Subclinical atrial fibrillation (SCAF)  
- Atrial high‑rate episode (AHRE)  
- Stroke (thrombo‑embolism)  
- Myocardial infarction  
- Heart failure  
- Coronary artery disease  
- Oral anticoagulation (OAC)  
- Non‑Vitamin K antagonist oral anticoagulants (NOACs)  
- Apixaban  
- Rivaroxaban  
- CHA₂DS₂‑VASc score  
- Sex modifier (female sex)  
- Rhythm monitoring (continuous)  
- Device‑detected subclinical AF  
- Stroke risk assessment  
- ECG (electrocardiogram)  
- Anticoagulation strategy  
- INTERVENTION trials (ARTESiA, COMMANDER HF, COMPASS, NOAH)  
- Stroke‑risk threshold (e.g., >1 % per year, ≥3.8)  
- Subclinical AF duration (>24 h, >23.5 h, >6 min‑24 h)

Page 42 Extracted Terms:
**Key Heart‑Disease Terms Identified**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Subclinical atrial fibrillation (subclinical AF)  
- Atrial high‑rate episodes (AHREs)  
- Stroke (ischemic stroke)  
- Systemic embolism  
- Transient ischemic attack (TIA) – implied in stroke discussion  
- Major bleeding  
- Oral anticoagulation (OAC)  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Antiplatelet therapy (e.g., Plavix) – referenced in ASAP study  
- Left atrial appendage (LAA)  
- Left atrial appendage occlusion (LAAO)  
- Percutaneous LAA occlusion (pLAAO)  
- Surgical LAA occlusion (LAAO)  
- Watchman device (standard and Watchman FLX)  
- Implantable cardioverter‑defibrillators (ICDs)  
- Pacemakers  
- CHA₂DS₂‑VASc score  
- CHADS₂ score  
- Sex‑modified CHA₂DS₂‑VASc score  
- Non‑valvular atrial fibrillation  
- High‑risk of stroke  
- Moderate‑to‑high risk of stroke  
- High risk of major bleeding  
- Contraindication to long‑term OAC  
- Nonreversible cause of OAC contraindication  
- Procedural success rate  
- Procedural risk (procedure‑related complications)  
- Systemic embolism prevention (embolization)  
- Embolic risk reduction  
- Stroke risk reduction  

These terms capture the core cardiovascular conditions, interventions, risk stratification tools, and therapeutic strategies discussed in the guideline excerpt.

Page 43 Extracted Terms:
- Atrial fibrillation  
- Left atrial appendage  
- Left atrial appendage occlusion (LAAO)  
- Surgical left atrial appendage occlusion (S‑LAAO)  
- WATCHMAN device  
- Oral anticoagulation  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Anticoagulant therapy  
- Stroke  
- Transient ischemic attack (TIA)  
- Systemic embolism  
- Cardiovascular death  
- All‑cause mortality  
- Major bleeding  
- Minor bleeding  
- CHA2DS2‑VASc score  
- Coronary artery bypass graft (CABG)  
- Valve surgery  
- Cardiac surgery  
- Thromboembolism  
- Suture line  
- Trans‑esophageal echocardiography (TEE)  
- Procedure‑related complications  
- LAAOS III (Left Atrial Appendage Occlusion Study)  
- PROTECT AF trial  
- PREVAIL trial  
- PRAGUE‑17 trial  
- Antithrombotic regimen  
- Intracranial bleeding  
- Gastrointestinal bleeding  
- Pulmonary bleeding  
- Genitourinary bleeding  
- Stroke prevention strategies  
- Anticoagulant stewardship  
- Non‑valvular atrial fibrillation  
- LAA exclusion/excision  
- Implant success  
- Device‑related complications

Page 44 Extracted Terms:
- Atrial fibrillation (AF)  
- Left atrial appendage (LAA)  
- Surgical left atrial appendage occlusion (S‑LAAO)  
- LAAOS III trial  
- LAA closure techniques (amputation, stapler, double‑layer linear, device)  
- CHA₂DS₂‑VASc score  
- Oral anticoagulation (OAC)  
- Dabigatran  
- Idarucizumab  
- Activated prothrombin complex concentrate (PCC)  
- Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban)  
- Andexanet alfa  
- Stroke  
- Systemic embolism  
- Thromboembolism  
- CABG (coronary artery bypass grafting)  
- Valve surgery (mechanical, bioprosthetic)  
- Mechanical valve surgery  
- Transplant surgery  
- Off‑pump bypass  
- Left ventricular assist device (LVAD)  
- Congenital heart disease (CHD)  
- Cross‑clamp time  
- Bypass time  
- Chest tube output  
- Peri‑operative bleeding  
- Transesophageal echocardiography (TEE)  
- Ischemic events  
- Mortality  
- Meta‑analysis  
- Randomized controlled trials (RCTs)  
- Systematic review  
- LAACS study (Left Atrial Appendage Closure with Surgery)

Page 45 Extracted Terms:
- Atrial fibrillation  
- Anticoagulation therapy  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
  - Dabigatran  
  - Apixaban  
  - Rivaroxaban  
  - Edoxaban  
- Vitamin K  
- 4‑factor prothrombin complex concentrate (PCC)  
- Activated prothrombin complex concentrate (aPCC)  
- Idarucizumab (dabigatran reversal agent)  
- Andexanet alfa (factor Xa inhibitor reversal agent)  
- International Normalized Ratio (INR)  
- Prothrombin time (PT)  
- Activated partial thromboplastin time (aPTT)  
- Ecarin clotting time  
- Thrombin time  
- Factor Xa inhibition  
- Hemostasis  
- Major bleeding  
- Life‑threatening bleeding  
- Gastrointestinal bleeding  
- Reversal agents  
- Fresh frozen plasma  
- Hemodialysis (for dabigatran elimination)  
- Activated charcoal (for OAC ingestion)  
- Bleeding risk assessment  
- Thromboembolic events  
- Shared decision making (SDM)  
- Multidisciplinary team approach  
- Emergency department visit for OAC-related bleeding  
- Stroke risk in atrial fibrillation  
- Cardiovascular complications of anticoagulation  
- Cardiac rhythm disorders (in the context of AF)

Page 46 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation  
- Venous thromboembolism  
- Arterial thromboembolism  
- Myocardial infarction  
- Ischemic stroke  
- Cardiac arrest  
- Sudden death  
- Reversal of anticoagulation (for heart‑related indications)  
- 4‑factor prothrombin complex concentrate (PCC)  
- Activated PCC  
- Idarucizumab (dabigatran reversal)  
- Andexanet alfa (factor Xa inhibitor reversal)  
- Apixaban  
- Rivaroxaban  
- Dabigatran  
- Vitamin K administration (for VKA reversal)  
- Warfarin  
- Vitamin K antagonists (VKA)  
- INR (International Normalized Ratio)  
- Coagulation factors II, VII, IX, X  
- Factor Xa inhibitors  
- Factor IX (units)  
- aPTT (activated partial thromboplastin time)  
- Thrombophilia (implied by procoagulant therapy)  
- Acute major bleeding (life‑threatening, emergency surgery)  
- Prophylaxis of bleeding in hemophilia (impacts cardiac surgical risk)  
- Black box warning for life‑threatening adverse events (arterial/venous thromboembolism, myocardial infarction, ischemic stroke, cardiac arrest)  

These terms encompass the main clinical entities, medications, and laboratory measures described in the guideline excerpt that are directly relevant to cardiovascular (heart) disease.

Page 47 Extracted Terms:
- Atrial fibrillation (AF)  
- Anticoagulation therapy  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Edoxaban  
- Mechanical heart valve  
- Rheumatic heart disease  
- Intracranial hemorrhage (ICH)  
- Cerebral amyloid angiopathy  
- Left atrial appendage occlusion (LAAO)  
- Thromboembolic events  
- Stroke (ischemic stroke)  
- Cerebrovascular events  
- Major bleeding  
- Gastrointestinal bleeding  
- Intracerebral hemorrhage  
- Intracranial bleeding  
- Anticoagulant resumption  
- Timing of anticoagulant restart  
- Anticoagulant-sparing strategies  
- Recurrent ICH  
- Oral anticoagulant discontinuation  
- Recurrent gastrointestinal bleeding  
- Bleeding risk assessment  
- Anticoagulation risk–benefit assessment  
- Bleeding events per year (in trials)  
- Hazard ratio (HR)  
- Relative risk (RR)  



Page 48 Extracted Terms:
- Atrial fibrillation (AF)  
- Mechanical heart valves  
- Rheumatic valvular disease  
- Anticoagulation therapy  
- Thromboembolic complications  
- Embolic events  
- Left atrial appendage (LAA) closure  
- Mechanical valve-related embolic risk  
- Embolic event risk per year (e.g., >5% per year)  
- Mechanical valve type‑dependent thrombogenicity (e.g., 4%–23% per year)

Page 49 Extracted Terms:
- Atrial fibrillation (AF)  
- Valve disease  
- Mechanical heart valve  
- Rheumatic valve disease  
- Anticoagulation therapy  
- Vitamin K antagonist (VKA; e.g., warfarin)  
- Direct oral anticoagulants (DOACs)  
- Thromboembolism / thromboembolic complications  
- Left atrial appendage (LAA) closure  
- Stroke (ischemic stroke, hemorrhagic stroke)  
- Systemic embolism  
- Intraparenchymal hemorrhage (ICH)  
- CHA2DS2‑VASc score (including congestive heart failure)  
- Congestive heart failure  
- Cardiac thrombus formation  

These terms capture the primary heart‑disease concepts addressed in the cited guidelines.

Page 50 Extracted Terms:
- Atrial fibrillation (AF)  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Periprocedural anticoagulation management  
- Thromboembolism / thromboembolic risk  
- Bridging anticoagulation  
- Heparin (including low‑molecular‑weight heparin)  
- Pacemaker implantation  
- Implantable cardioverter‑defibrillator (ICD) implantation or generator change  
- Mechanical heart valve  
- Stroke  
- Transient ischemic attack (TIA)  
- CHA₂DS₂‑VASc score  
- CHADS₂ score  
- High bleeding‑risk procedures (e.g., cardiac, orthopedic, neurosurgical, transvenous lead extraction)  
- Low bleeding‑risk procedures (e.g., endoscopic, dental extraction, ophthalmologic, percutaneous catheterization)  
- Cardiac catheterization  
- Transvenous lead extraction  
- Neuraxial anesthesia / spinal surgery  
- Renal dysfunction (creatinine clearance – CrCl)  
- Hepatic dysfunction  
- Anemia  
- Antiplatelet therapy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Intravenous anticoagulation interruption timing (e.g., days of hold for specific DOACs)  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Rivaroxaban  
- International Normalized Ratio (INR) target values  
- Resumption of anticoagulation post‑procedure (timing relative to bleeding risk)

Page 51 Extracted Terms:
- Atrial fibrillation  
- Congestive heart failure  
- Heart failure  
- Stroke  
- Transient ischemic attack (TIA)  
- Thromboembolism / thromboembolic events  
- Direct oral anticoagulant (DOAC)  
- Warfarin (Coumadin)  
- Mechanical valve  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Pocket hematoma  
- Lead extraction procedure  
- Bleeding risk (low‑bleeding‑risk procedures, high‑bleeding‑risk procedures)  
- Bridging anticoagulation  
- Periprocedural anticoagulation management  
- CHADS2 score  
- CHA₂DS₂‑VASc score  
- Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) cohort  
- BRUISE‑CONTROL study  
- Anticoagulation interruption (brief interruption)  
- Uninterrupted anticoagulation  



Page 52 Extracted Terms:
**Key heart‑disease terms extracted from the guidelines**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Coronary artery disease (CAD)  
- Acute coronary syndrome (ACS)  
- Percutaneous coronary intervention (PCI)  
- Dual antithrombotic therapy  
- Triple therapy (OAC + P2Y12 inhibitor + aspirin)  
- Aspirin  
- P2Y12 inhibitor (e.g., clopidogrel, ticagrelor, prasugrel)  
- Antiplatelet therapy (APT)  
- Direct oral anticoagulants (DOACs)  
  - Apixaban  
  - Dabigatran  
  - Rivaroxaban  
  - Edoxaban  
- Vitamin K antagonists (VKAs)  
  - Warfarin  
- Bridging anticoagulation (pre‑ and post‑procedure)  
- Mechanical heart valves  
- Valvular heart disease  
- Stent implantation  
- Thromboembolism (e.g., stroke, systemic embolism)  
- Stroke prevention in AF  
- Bleeding risk assessment (low‑ vs high‑risk procedures)  
- Periprocedural events  
- Anticoagulation interruption and resumption timing  
- Post‑operative bridging  
- Low‑molecular‑weight heparin (LMWH)  
  - Dalteparin  
- International Normalized Ratio (INR)  
- Clinically relevant bleeding  
- Paroxysmal atrial flutter  
- Cardiac rhythm management  
- Cardiovascular disease (general umbrella term)

Page 53 Extracted Terms:
- Atrial fibrillation  
- Coronary artery disease  
- Chronic coronary disease  
- Percutaneous coronary intervention (PCI)  
- Stent thrombosis  
- Antiplatelet therapy (APT)  
- Aspirin  
- P2Y12 inhibitor  
- Direct oral anticoagulant (DOAC)  
- Vitamin K antagonist (VKA)  
- Dual antithrombotic therapy (DAT)  
- Triple antithrombotic therapy (TAT)  
- Clinically relevant bleeding  
- Major bleeding  
- Ischemic events  
- Stroke  
- Systemic embolism  
- Mechanical valve  
- Complex revascularization  
- Multivessel PCI  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Edoxaban  
- PIONEER AF‑PCI  
- RE‑DUAL PCI  
- AUGUSTUS  
- ENTRUST‑AF PCI  
- WOEST  
- Meta‑analysis  
- International Society on Thrombosis and Haemostasis (ISTH)  
- Number needed to treat (NNT)  
- Noninferior (study outcome)  
- Risk of bleeding  
- Risk of stent thrombosis  
- Antithrombotic regimen  
- Oral anticoagulation monotherapy  
- Combination therapy of OAC and single APT  
- Aspirin placebo  
- Recurrent cardiovascular events  
- 1‑year post‑revascularization period  




Page 54 Extracted Terms:
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Coronary revascularization (including coronary stenting)  
- Oral anticoagulation (OAC)  
- Rivaroxaban  
- Dual therapy (OAC plus antiplatelet therapy)  
- Antiplatelet therapy (APT)  
- Stent thrombosis  
- Peripheral artery disease (PAD)  
- Myocardial infarction (MI)  
- Stroke (cerebrovascular accident)  
- Systemic embolism  
- Unstable angina  
- Vascular death  
- Major bleeding (intracranial hemorrhage, life‑threatening hemorrhage)  
- Intracranial hemorrhage (ICH)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- ENGAGE AF‑TIMI 48 trial  
- ARISTOTLE trial  
- ROCKET AF trial  
- WAVE (Warfarin‑Antiplatelet Vascular Evaluation) trial  
- Dual antiplatelet therapy (DAT)  
- Antiplatelet monotherapy  
- Lower extremity revascularization  
- Acute limb ischemia  
- Critical limb ischemia  
- Amputation  
- Major adverse cardiac events (MACE)  
- Composite outcome (stroke, systemic embolism, MI, unstable angina requiring revascularization, death from any cause)  
- Revascularization (in PAD and CAD contexts)  
- Inter­mediate‑to‑high risk of stroke (in AF patients)

Page 55 Extracted Terms:
- Atrial Fibrillation (AF)  
- Stroke (ischemic stroke)  
- Anticoagulation  
- Oral Anticoagulants (OAC)  
- Warfarin  
- Direct Oral Anticoagulants (DOACs)  
- Apixaban  
- Rivaroxaban  
- Dabigatran  
- Dual therapy (OAC + APT)  
- Antiplatelet therapy (APT)  
- Aspirin  
- Major adverse cardiac events (MACE)  
- Major bleeding  
- Bleeding risk  
- Thromboembolism  
- Left atrial appendage occlusion (LAAO)  
- End‑stage renal disease (ESRD)  
- Dialysis / Hemodialysis  
- Calciphylaxis  
- Time in therapeutic range (TTR)  
- International Normalized Ratio (INR)  
- Renal function (eGFR, CrCl) – risk modifiers for cardiac outcomes  
- Cardiac anticoagulation therapy  
- Cardiovascular risk in CKD  

These terms capture the key heart‑disease concepts referenced in the guideline text.

Page 56 Extracted Terms:
- Atrial fibrillation (AF)  
- Valvular heart disease (VHD)  
- Rheumatic mitral stenosis  
- Moderate or greater mitral stenosis  
- Mechanical heart valve  
- Mechanical aortic valve  
- Mechanical mitral valve  
- Mitral regurgitation  
- Aortic stenosis  
- Bioprosthetic valve  
- Valve repair  
- Anticoagulation therapy  
- Warfarin (vitamin K antagonist)  
- Direct oral anticoagulants (DOACs) – e.g., apixaban, dabigatran, edoxaban, rivaroxaban  
- Vitamin K antagonists (VKAs)  
- Stroke  
- Systemic thromboembolism  
- Myocardial infarction (MI)  
- Thromboembolic events  
- CHA₂DS₂‑VASc score  
- INVICTUS clinical trial  
- ENGAGE AF trial  
- ARISTOTLE trial  
- ROCKET‑AF trial  
- RE‑ALIGN trial  
- PROACT‑Xa trial  
- Creatinine clearance (CrCl)  
- Renal function (e.g., dosage adjustments for DOACs)

Page 57 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL) – typical (CTI‑dependent) and atypical (non‑CTI)  
- Atrial tachycardia (AT)  
- Atrial arrhythmia  
- Anticoagulation therapy  
- Thromboembolic risk  
- Stroke (ischemic)  
- Thrombus formation (LA thrombus, LAA thrombus)  
- Left atrial (LA)  
- Left atrial appendage (LAA)  
- Cardiac cardioversion  
- Catheter ablation  
- CTI (cavotricuspid isthmus) ablation  
- Atrial stunning (LA/LAA)  
- Pulmonary venous‑related factors (e.g., chronic obstructive pulmonary disease – COPD)  
- Heart failure (HF)  
- Risk assessment for stroke (≥2 % annual risk)  
- Silent atrial fibrillation (AF) detection/monitoring  
- Electro‑cardiographic (ECG) criteria for AFL/AF  
- Echo‑contrast / spontaneous echo contrast (SEC)  
- Hemodynamic and structural remodeling (LA enlargement, scar tissue)  
- Guideline‑based recommendations for anticoagulation duration (≥4 weeks post‑procedure)  
- Catheter ablation outcomes (success, recurrence)  

These terms capture the key cardiovascular concepts discussed in the guideline excerpt regarding atrial arrhythmias and their management.

Page 58 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Oral anticoagulation  
- Thromboembolism  
- Stroke  
- Systemic thromboembolism  
- Cavotricuspid isthmus (CTI)  
- Catheter ablation  
- AF ablation  
- AFL ablation  
- Left atrial (LA) enlargement  
- Interatrial conduction time  
- Prolonged HV interval  
- Chronic obstructive pulmonary disease (COPD)  
- Obstructive sleep apnea  
- HATCH score (Hypertension, Age ≥75 years, TIA or stroke, COPD, Heart failure)  
- Hypertension  
- Transient ischemic attack (TIA)  
- Heart failure  
- Implantable cardiac monitor  
- Ambulatory monitor  
- Wearable device  
- Cryptogenic stroke  
- Inducible AF  
- Thromboembolic event rate  
- Ablation success rate  
- Monitoring (intermittent, continuous)  
- Stroke risk assessment  
- New‑onset AF  
- Permanent AF  
- Paroxysmal AF  
- Persistent AF  
- Permanent AFL (for completeness)

Page 59 Extracted Terms:
**Key heart‑disease related terms from the guideline**

- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiovascular causes of death  
- Stroke  
- Systemic embolism  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sick sinus syndrome  
- Tachycardia–bradycardia (sick sinus) syndrome  
- Rate control (strategies, targets, intensity)  
- Rhythm control (strategies, outcomes)  
- RACE II study  
- AFFIRM study  
- HOT CAFE trial  
- ORBIT‑AF trial  
- All‑cause mortality  
- Cardiac mortality  
- Non‑invasive management (rate‑control pharmacology)  

These terms capture the central heart‑disease concepts and outcomes discussed in the guideline.

Page 60 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Left ventricular systolic dysfunction (LVSD)  
- Heart failure (HF)  
- HFrEF (heart failure with reduced ejection fraction)  
- B‑mode/β‑blockers  
- Nondihydropyridine calcium‑channel blockers  
- Diltiazem  
- Verapamil  
- Digoxin  
- Amiodarone  
- Intravenous magnesium  
- Intravenous rate‑control agents  
- Acute rate control  
- Long‑term rate control  
- Ejection fraction (EF >40%)  
- Tachycardia‑induced cardiomyopathy  
- Cardioversion  
- Stroke prevention in AF  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Biventricular pacing  
- Myocardial recovery  
- Tachycardia‑bradycardia syndrome  
- Sick sinus syndrome  
- Decompensated heart failure  
- Hypotension (related to rate‑control therapy)

Page 61 Extracted Terms:
- Atrial fibrillation  
- Rapid ventricular response  
- Intravenous diltiazem  
- Intravenous digoxin  
- Intravenous amiodarone  
- Intravenous magnesium  
- Beta blockers  
- Metoprolol tartrate  
- Metoprolol succinate  
- Atenolol  
- Bisoprolol  
- Carvedilol  
- Esmolol  
- Nadolol  
- Propranolol  
- Nondihydropyridine calcium‑channel blockers  
- Diltiazem (oral)  
- Verapamil  
- Digitalis glycoside (digoxin)  
- Amiodarone (oral)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure  
- Antiarrhythmics  
- Rate control  
- Ventricular rate  
- Arrhythmias  
- Coronary artery bypass graft (CABG)

Page 62 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Rate control  
- Rhythm control  
- Intravenous magnesium  
- Standard rate‑control methods (beta blockers, diltiazem, verapamil, digoxin)  
- Intravenous amiodarone  
- Intravenous diltiazem  
- Intravenous metoprolol  
- Heart rate (HR)  
- Hemodynamic stability (blood pressure, BP)  
- Hypotension  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Acute kidney injury (AKI)  
- Inotropic support  
- Negative inotropic effect  
- AV nodal blocker  
- Intensive care unit (ICU) setting  
- Pulmonary oxygen requirement  
- Mortality (in‑hospital)  
- LV dysfunction  
- Left ventricle (LV)

Page 63 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Long‑term rate control  
- Beta blockers  
- Nondihydropyridine calcium channel blockers  
  - Verapamil  
  - Diltiazem  
- Digoxin  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Dronedarone  
- Cardiovascular events  
- Ventricular rate control  
- Electrocardiographic abnormalities  
- Serum digoxin concentration / therapeutic range  
- Digoxin toxicity  
- DIG (Digitalis Investigation Group) trial  
- RATE‑AF trial  
- N‑terminal pro‑brain natriuretic peptide (NT‑proBNP)  
- Chronic rate control  
- Pre‑excitation (in the context of ventricular rate control)  
- Reactive airway disease (as a comorbidity affecting drug choice)  
- Hemodynamics (e.g., heart rate, blood pressure)  
- Hospitalization and all‑cause mortality outcomes  

These terms capture the main clinical concepts and interventions discussed in the guideline excerpt.

Page 64 Extracted Terms:
Atrial fibrillation  
Heart failure  
Heart failure with reduced ejection fraction (HFrEF)  
Left ventricular ejection fraction (LVEF)  
Myocardial infarction (MI)  
Congestive heart failure (CHF)  
Digoxin  
Diltiazem  
Dronedarone  
Arrhythmia  
Stroke  
Ventricular response / ventricular rate  
Ventricular dysfunction  
Pacemaker implantation  
Atrioventricular nodal ablation (AVNA)  
Conduction system pacing  
His bundle pacing  
Left bundle branch area pacing  
Non‑dihydropyridine calcium channel blocker (NDCC)  
Ventricular tachycardia  
Mortality  
Resting heart rate  
Meta‑analysis of digoxin use  
PALLAS study  
ERATO trial  

Page 65 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrioventricular nodal ablation (AVNA)  
- Right ventricular pacing (RVP)  
- Bi‑ventricular pacing (BiVP)  
- His bundle pacing  
- Left bundle branch area pacing  
- Pacemaker implantation  
- Heart failure (HF)  
- Sudden cardiac death  
- Ventricular fibrillation (VF)  
- Malignant arrhythmias  
- QT interval prolongation  
- Ejection fraction (EF)  
- New York Heart Association (NYHA) class II/III  
- Lead dislodgement / lead failure  
- Pneumothorax  
- Anti‑arrhythmic drug therapy  
- Stroke risk  
- 6‑minute walk test (functional capacity)  
- Quality‑of‑life outcomes  
- Hospitalization (HF‑related)  
- Survival / all‑cause mortality  
- Rate control strategies (medical vs device)

Page 66 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Atrial fibrillation (AF)  
- Persistent atrial fibrillation  
- High‑burden atrial fibrillation  
- Symptomatic atrial fibrillation  
- Rhythm control  
- Rate control  
- Antiarrhythmic drugs (AADs)  
- AF ablation  
- Heart failure (HF)  
- Left ventricular (LV) function  
- Ejection fraction (EF)  
- Reduced LVEF / reduced LV function  
- Ischemia  
- Stroke  
- Mortality  
- Hospitalization for heart failure  
- Cardiac hospitalization  
- AF burden  
- Rapid ventricular rates  
- Left bundle‑area pacing  
- His bundle pacing  
- Conduction‑system pacing  
- Atrioventricular nodal ablation (AVNA)  
- EAST‑AFNET 4 trial  
- RACE II study  

These terms capture the primary cardiovascular concepts and interventions discussed in the guideline excerpt.

Page 67 Extracted Terms:
- Atrial fibrillation  
- Rhythm control  
- Rate control  
- Cardiovascular death  
- Ischemic stroke  
- Hospitalization for ischemia  
- Heart failure (HF)  
- AF‑CHF (Atrial Fibrillation and Congestive Heart Failure) trial  
- Left ventricular (LV) function  
- Catheter ablation  
- Composite primary endpoint  
- Mortality rate  
- Sinus rhythm  
- Amiodarone  
- Antiarrhythmic drugs  
- CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy)  
- EAST‑AFNET 4 trial  
- Cardiovascular mortality  
- Quality of life (QOL)  
- Emergency department visits  
- Health care resource utilization  
- Acute ischemic syndrome  
- Clinical outcomes  
- Left atrium (LA)  
- Atrioventricular (AV)  

(Note: Terms are listed as key concepts related to heart disease found in the provided text.)

Page 68 Extracted Terms:
- Atrial fibrillation (AF)  
- CASTLE‑AF trial  
- AF‑CHF study  
- Rhythm control strategy  
- Rate control strategy  
- Left ventricular dysfunction  
- Heart failure (HF)  
- Asymptomatic AF  
- Symptomatic AF  
- Stroke  
- Cardiovascular death  
- Hospitalization for heart failure  
- Catheter ablation  
- EAST‑AFNET 4 study  
- AF progression  
- AF burden  
- Left atrial (LA) size  
- Heart rate  
- Modifiable risk factors  
- Circulation (journal reference for guideline)

Page 69 Extracted Terms:
- Atrial fibrillation (AF)  
- Mitral regurgitation  
- Tricuspid regurgitation  
- Left atrial (LA) size  
- Left atrial appendage (LAA)  
- Left atrial appendage occlusion (LAAO)  
- Cardioversion (electrical and pharmacological)  
- Thromboembolism  
- Anticoagulation  
- Direct oral anticoagulants (DOACs)  
- Vitamin K antagonists (VKAs)  
- Heart failure (HF)  
- Cognitive impairment  
- Dementia  
- Atrial myopathy  
- Atrial stunning  
- Acute rhythm control  
- Hemodynamic instability  
- CHA2DS2‑VASc score  
- Intracardiac thrombus  
- Atrial mechanical dysfunction (loss of atrial kick, dyssynchrony)

Page 70 Extracted Terms:
- Atrial fibrillation  
- Cardioversion  
- Anticoagulation (therapeutic, VKAs, DOACs)  
- Thromboembolism / thromboembolic risk  
- Intracardiac thrombus  
- Cardiac computed tomography (delayed contrast‑enhanced imaging)  
- Transesophageal echocardiography (TEE)  
- Atrial dysfunction  
- Atrial stunning  
- Mechanical atrial systole  
- Left atrial appendage occlusion (LAAO)  
- Early recurrence of atrial fibrillation  
- Hemodynamically stable atrial fibrillation  
- Post‑cardioversion anticoagulation period  
- Clinical variables influencing atrial recovery  
- Thromboembolic events within 30 days of cardioversion

Page 71 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Non‑valvular atrial fibrillation  
- Intracardiac thrombus  
- Left atrial appendage (LAA) thrombus  
- Left atrial appendage occlusion (LAAO)  
- Percutaneous LAAO (pLAAO)  
- Watchman device  
- Lariat procedure  
- Residual leak  
- Device‑related thrombosis  
- Stroke  
- Systemic embolism  
- Thromboembolism  
- Anticoagulation therapy  
- Anticoagulant‑naïve patients  
- Vitamin K antagonist (VKA)  
- Rivaroxaban  
- Oral anticoagulation (OAC)  
- Transesophageal echocardiography (TEE)  
- Computed tomography (CT/CTA)  
- CHA₂DS₂‑VASc score  
- Cardioversion (electrical cardioversion)  
- Pericardioversion anticoagulation  
- Post‑cardioversion thromboembolic risk  
- Subtherapeutic anticoagulant levels  
- Drug adherence/compliance  
- Drug absorption and drug interactions  
- CLOT‑AF registry  
- X‑TRA study  
- Incidence of thromboembolic events  
- Anticoagulant dosing appropriateness  
- Anticoagulant compliance assessment  



Page 72 Extracted Terms:
- Atrial fibrillation (AF)  
- Ventricular fibrillation (VF)  
- Sinus rhythm  
- Electrical cardioversion  
- Pharmacological cardioversion  
- CHA₂DS₂‑VASc score  
- Pericardioversion thromboembolic event/risk  
- Biphasic energy (≥200 J)  
- Energy delivery synchronization to QRS  
- Electrode vector optimization  
- Transthoracic impedance  
- Manual pressure augmentation  
- Left atrial (LA) size  
- Hemodynamic instability / instability  
- Acute rhythm control  
- Antiarrhythmic drugs (AADs)  
- Sedation  
- FinCV study  
- RAFF2 study  
- Acute rhythm-control strategy  
- Rhythm‑control strategy  
- High‑risk scoring  
- Success of sinus rhythm restoration  
- Recurrence of atrial fibrillation (AF)  
- Cardioversion energy  
- Direct current cardioversion (DCCV)

Page 73 Extracted Terms:
- Atrial fibrillation (AF)  
- Hemodynamically stable AF  
- Electrical cardioversion  
- Unsynchronized vs. synchronized cardioversion  
- Ventricular fibrillation (VF)  
- QRS complex  
- Biphasic waveform  
- Monophasic waveform  
- Sinus rhythm  
- Trans‑tracheal impedance  
- Defibrillator (dual‑device use)  
- Pharmacologic cardioversion  
- Ibutilide  
- Amiodarone (intravenous)  
- Flecainide (pill‑in‑the‑pocket)  
- Propafenone (pill‑in‑the‑pocket)  
- Procainamide (intravenous)  
- Atrioventricular nodal blocking agent  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced EF (HFrEF)  
- QT interval prolongation  
- Torsades de pointes  
- Persistent vs. new‑onset AF  
- Energy escalation (high‐fixed vs. low‑escalating)  
- Electrode vector orientation (anterior‑posterior, anterior‑lateral)  
- Transthoracic impedance  
- Obesity related cardioversion challenges  
- Thromboembolic complications  
- Hemodynamic complications of cardioversion  
- Anesthesia effects during cardioversion  
- Pharmacologic agents for rhythm control  
- Monitoring for rhythm conversion  
- “Pill‑in‑the‑pocket” approach  
- Pharmacologic cardioversion timing (8–12 h for amiodarone)  



Page 74 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardioversion (electrical and pharmacological)  
- Antiarrhythmic drugs  
  - Amiodarone  
  - Flecainide  
  - Propafenone  
  - Ibutilide  
  - Procainamide  
  - Sotalol  
- Intravenous (IV) drug administration  
- Oral drug administration  
- Ventricular tachycardia (VT)  
- Torsades de pointes (TdP)  
- Bradycardia  
- Hypotension  
- Atrioventricular (AV) block  
- QT interval prolongation  
- Agranulocytosis  
- Neutropenia  
- Thrombocytopenia  
- Rash  
- Dizziness  
- Dyspnea  
- Nausea  
- Visual disturbances  
- Taste disturbances  
- N-acetylprocainamide (NAPA)

Page 75 Extracted Terms:
**Key heart‑disease terms extracted**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Cardioversion  
- Direct current (DC) cardioversion / electrical cardioversion  
- Pharmacological cardioversion  
- Wait‑and‑watch strategy  
- Ibutilide  
- Intravenous amiodarone  
- Procainamide  
- Torsades de pointes  
- QT interval prolongation / extended QT interval  
- Left ventricular ejection fraction (LVEF)  
- Reduced LVEF (≤40 %)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Magnesium infusion  
- Electrocardiographic monitoring  
- Cardiac resuscitation  
- Post‑conversion bradycardia  
- Cardiac arrhythmia  
- Heart failure  
- Ventricular dysfunction  

These terms collectively cover the principal concepts of heart disease and arrhythmia management discussed in the excerpt.

Page 76 Extracted Terms:
- Atrial fibrillation (AF)  
- Sinus rhythm / conversion to sinus rhythm  
- Long‑term maintenance of sinus rhythm  
- Antiarrhythmic drugs  
- Flecainide  
- Propafenone  
- Dofetilide  
- Amiodarone (low‑dose)  
- Dronedarone  
- Sotalol  
- Procainamide (intravenous)  
- Ibutilide  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF, ≤40 %)  
- Left ventricular (LV) dysfunction / severe LV dysfunction  
- Myocardial infarction (MI)  
- Structural heart disease  
- Ventricular scar or fibrosis  
- QT interval (prolongation, monitoring)  
- Torsades de pointes  
- Proarrhythmia  
- Mortality (increased risk)  
- Decompensated heart failure  
- New‑York Heart Association (NYHA) class III/IV  
- Hypotension (clinically significant)  
- Hypokalemia  
- Hypomagnesemia  
- Bradycardia  
- Kidney function (renal dosing)  
- Serum potassium concentration  
- Serum magnesium concentration  
- β‑blocker therapy  
- Calcium channel blocker (non‑dihydropyridine)  
- Arrhythmia management strategies (pill‑in‑the‑pocket, catheter ablation)  
- Conversion rates (e.g., 58–68 % for flecainide, 45–57 % for propafenone)  

These terms capture the clinical concepts, interventions, and risk factors discussed in the guideline excerpt.

Page 77 Extracted Terms:
Atrial fibrillation (AF)  
Atrial flutter  
Heart failure (HF)  
Heart failure with reduced ejection fraction (HFrEF)  
Sinus rhythm  
Maintenance of sinus rhythm  
Antiarrhythmic agents  
Amiodarone  
Dofetilide  
Sotalol  
Flecainide  
Propafenone  
Dronedarone  
Beta blocker  
Atrioventricular nodal blocking agent  
Supraventricular tachycardia (SVT)  
Torsades de pointes  
QT interval prolongation  
Pulmonary fibrosis  
Hypothyroidism  
Hyperthyroidism  
Elevated transaminases  
Hepatotoxicity  
Photosensitivity  
Corneal microdeposits  
Optic neuropathy  
Peripheral neuropathy  
Sinus bradycardia  
Arrhythmia  
AF recurrence  
AF recurrence prevention  
Structural heart disease  
Scar  
Fibrosis  
Myocardial infarction (MI)  
Flec-SL trial  
SAFIRE-D study  
EURIDIS trial  
ADONIS trial  
SAFE‑T trial  
CTAF trial  
Dofetilide loading / reloading  
Creatinine clearance (CrCl)  
Cardiac resuscitation  
Continuous electrocardiographic monitoring

Page 78 Extracted Terms:
- Atrial fibrillation (AF)  
- Sotalol  
- Sinus rhythm  
- SAFE‑T  
- All‑cause mortality  
- Advanced heart failure (HF)  
- Preserved heart function  
- Creatinine clearance (CrCl)  
- Continuous electrocardiographic monitoring  
- Cardiac resuscitation  
- FDA‑approved intravenous sotalol formulation  
- CAST (Cardiac Arrhythmia Suppression Trial)  
- Vaughan‑Williams Class IC antiarrhythmic agents  
- Flecainide  
- Encainide  
- Mortality rate  
- Recent myocardial infarction (MI)  
- Left ventricular ejection fraction (LVEF) < 50%  
- CAST‑II  
- Moricizine  
- CASH (Cardiac Arrest Study Hamburg)  
- Propafenone  
- Structural heart disease  
- Heart failure with reduced ejection fraction (HFrEF)  
- Worsening HF  
- ANDROMEDA (Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease)  
- Dronedarone  
- Hospitalization attributable to HF  
- Arrhythmic death  
- New or worsening HF  
- New York Heart Association functional class (NYHA FC)  
- Intravenous (IV)  
- Left ventricle (LV)  
- Left ventricular ejection fraction (LVEF)  
- Myocardial infarction (MI)  
- New York Heart Association functional class (NYHA FC)

Page 79 Extracted Terms:
Heart failure (HF)  
Class III HF  
Class IV HF  
NYHA class II  
NYHA class III  
NYHA class IV  
Heart failure with reduced ejection fraction (HFrEF)  
Atrial fibrillation (AF)  
Atrial flutter (AFL)  
Dronedarone  
Dofetilide  
Sotalol  
Amiodarone  
Flecainide  
Propafenone  
Antiarrhythmic agents  
Class III antiarrhythmic drug  
Class I antiarrhythmic drug  
Bradyarrhythmia  
Tachyarrhythmia  
Proarrhythmia  
Torsades de pointes  
QTc prolongation  
Ventricular fibrillation (VF)  
Continuous electrocardiographic monitoring  
Cardiac resuscitation  
Creatinine clearance (CrCl)

Page 80 Extracted Terms:
- Atrial fibrillation (AF)  
- Sinus rhythm maintenance  
- Amiodarone  
- Dofetilide  
- Dronedarone  
- IKr (rapid delayed rectifier potassium current)  
- IKs (slow delayed rectifier potassium current)  
- INa (sodium current)  
- IKur (ultra‑rapid delayed rectifier potassium current)  
- Ito (transient outward potassium current)  
- ICa‑L (L‑type calcium current)  
- IKACh (acetylcholine‑activated potassium current)  
- Non‑competitive β‑blocker activity  
- AV block  
- Bradycardia  
- Corneal microdeposits  
- Transaminase elevation  
- Hepatotoxicity  
- Hyperthyroidism  
- Hypothyroidism  
- Nausea  
- QT‑prolongation  
- Torsades de pointes (TdP)  
- Peripheral neuropathy  
- Photosensitivity  
- Pulmonary fibrosis  
- Skin pigmentation (blue‑gray)  
- CYP2C9 inhibition (moderate)  
- CYP2D6 inhibition (weak)  
- CYP3A inhibition (moderate)  
- Cytochrome P450 interactions (e.g., warfarin, lovastatin, simvastatin)  
- P‑gp inhibition (increasing digoxin exposure)  
- Renal excretion via renal cation transport system  
- Dofetilide contraindications: cimetidine, dolutegravir, ketoconazole, megestrol, prochlorperazine, trimethoprim, verapamil, hydrochlorothiazide with triamterene  
- Dronedarone substrate and inhibitor of CYP3A and CYP2D6  
- Dronedarone substrate and inhibitor of P‑gp  
- Increased dronedarone plasma levels with grapefruit juice  
- Decreased dronedarone plasma levels by CYP3A inducers (St. John’s wort, rifampin, phenytoin)  
- Abrupt discontinuation complications (e.g., sudden onset AF)  
- Clinical guideline reference: 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation (Circulation 2024)

Page 81 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Proarrhythmia  
- Hypotension  
- Bradycardia  
- Syncope  
- Permanent pacemaker  
- Antiarrhythmic drug  
- Class IC agent  
- PITP strategy (high‑dose class IC therapy)  
- Flecainide  
- Propafenone  
- Sotalol  
- CYP2D6 metabolism  
- QT interval prolongation  
- Torsades de pointes (TdP)  
- Ventricular tachycardia (VT)  
- Bradyarrhythmia  
- AV nodal blocker  
- Sinus rhythm restoration  
- Cardioversion  
- Inotropic/chronotropic safety monitoring  
- Drug–drug interactions (e.g., with amiodarone, fluoxetine, paroxetine, digoxin, warfarin, statins)  
- Renal clearance (CrCl) and dosing adjustments  
- Extended‑release formulation (ER)  
- Liver and kidney elimination pathways  
- Inhibition of INa (sodium current)  
- Inhibition of IKr (potassium current)  
- Late INa augmentation (sotalol)  
- Pulmonary bronchospasm (sotalol adverse effect)  
- Diarrhea, fatigue, nausea (sotalol adverse events)  
- Visual disturbances (flecainide/propafenone)  
- Taste disturbances (propafenone)  
- Exacerbation of HFrEF (antiarrhythmic adverse effect)  
- QT prolongation‑related arrhythmogenic risk  

*(All terms are directly referenced in the guideline text and pertain to heart‑related disease concepts, therapies, and safety considerations.)*

